A recent phase III trial has found that high-dose pharmaceutical-grade biotin (MD1003) does not improve disability or walking speed in people with progressive multiple sclerosis (MS).
This outcome disappointed researchers because an earlier trial had found that biotin, which is known as vitamin B7, improved disability outcomes over 12 months. Scientists had previously hoped that the water-soluble vitamin might help to target remyelination because a previous study showed an improvement in disability, but the research has since been criticised for its methodology.
Investigators of the randomised, double-blind, placebo-controlled study conclude that high-dose biotin is not recommended for treatment of progressive MS.
The study was published in Lancet Neurology.
Source: MS-UK 02 November 2020